Psilocybin-assisted Therapy for Alcohol Use Disorder

This double-blind, randomised, Phase II trial (n=90) will evaluate the efficacy of psilocybin-assisted therapy (25mg) for reducing alcohol consumption in individuals with Alcohol Use Disorder (AUD).

Conducted by the University of Sydney, the study compares the effects of psilocybin (25mg) combined with psychotherapy against a control treatment of niacin (250mg) and psychotherapy. Over a 14-week period, participants will receive 12 therapy sessions and two dosing sessions with either psilocybin or niacin.

The primary outcome is the frequency of heavy drinking days, while secondary outcomes include overall alcohol consumption, anxiety, depression, and quality of life.

The trial aims to assess the potential of psilocybin to improve drinking patterns and psychological well-being in individuals with AUD.

Topic Alcohol Use Disorder Addiction
Compound Psilocybin Placebo
Country Australia
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Sydney
The University of Sydney is Australias oldest university. At the psychopharmacology laboratory, researchers have conducted some research with psychedelics.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.